CIA
JAZZ icon

Concurrent Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Concurrent Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,824
Closed -$701K – 1043
2024
Q1 		$701K Buy
+5,824
New +$713K 0.03% 459

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Concurrent Investment Advisors's JAZZ Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 5,824 shares — an estimated $701K sold.

Concurrent Investment Advisors first reported a position in JAZZ in Q1 2024 and held it in 1 quarter. The position peaked at $701K in Q1 2024. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 5,824 Jazz Pharmaceuticals shares in Q2 2024, an estimated $701K.
  • Concurrent Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Concurrent Investment Advisors's Jazz Pharmaceuticals position peaked at $701K in Q1 2024.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.